Skip to main content
PMC home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1995 Mar;114(5):925–930. doi: 10.1111/j.1476-5381.1995.tb13292.x

Role of endothelin-1 and the ETA receptor in the maintenance of deoxycorticosterone acetate-salt-induced hypertension.

K Fujita 1, Y Matsumura 1, S Kita 1, Y Miyazaki 1, K Hisaki 1, M Takaoka 1, S Morimoto 1
PMCID: PMC1510306  PMID: 7780646

Abstract

1. To search for a possible role for endothelin-1 (ET-1) in deoxycorticosterone acetate (DOCA)-salt-induced hypertension, we examined changes in concentration of ET-1 in vascular and renal tissue in DOCA-salt hypertensive rats and evaluated the antihypertensive effect of the ETA receptor antagonist, FR139317. 2. There was an increase in aortic immunoreactive-ET (IR-ET) concentrations in association with hypertension-induced treatment. There were no significant changes in ET-1 levels in the kidney with DOCA-salt treatment. 3. In DOCA-salt hypertensive rats, a significant correlation (r = 0.83, P < 0.01) was found between aortic IR-ET concentrations and systolic blood pressure. 4. High-performance liquid chromatography analysis of the aortic extract from DOCA-salt rats revealed one major component corresponding to the elution position of synthetic ET-1. 5. The intravenous bolus injection of FR139317 (10 mg kg-1) produced a slight decrease in blood pressure in the control rats and in the DOCA-salt hypertensive rat, FR139317 had a more pronounced hypotensive effect. 6. We propose that ET-1 production in vascular tissues is increased in DOCA-salt hypertensive rats. In addition, our study indicates the pathophysiological importance of increased endogenous ET-1 in the maintenance of DOCA-salt-induced hypertension, through interaction of the peptide with ETA receptors.

Full text

PDF
928

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bazil M. K., Lappe R. W., Webb R. L. Pharmacologic characterization of an endothelinA (ETA) receptor antagonist in conscious rats. J Cardiovasc Pharmacol. 1992 Dec;20(6):940–948. doi: 10.1097/00005344-199212000-00014. [DOI] [PubMed] [Google Scholar]
  2. Benigni A., Zoja C., Corna D., Orisio S., Longaretti L., Bertani T., Remuzzi G. A specific endothelin subtype A receptor antagonist protects against injury in renal disease progression. Kidney Int. 1993 Aug;44(2):440–444. doi: 10.1038/ki.1993.263. [DOI] [PubMed] [Google Scholar]
  3. Bigaud M., Pelton J. T. Discrimination between ETA- and ETB-receptor-mediated effects of endothelin-1 and [Ala1,3,11,15]endothelin-1 by BQ-123 in the anaesthetized rat. Br J Pharmacol. 1992 Dec;107(4):912–918. doi: 10.1111/j.1476-5381.1992.tb13385.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Clozel M., Breu V., Burri K., Cassal J. M., Fischli W., Gray G. A., Hirth G., Löffler B. M., Müller M., Neidhart W. Pathophysiological role of endothelin revealed by the first orally active endothelin receptor antagonist. Nature. 1993 Oct 21;365(6448):759–761. doi: 10.1038/365759a0. [DOI] [PubMed] [Google Scholar]
  5. Crofton J. T., Share L., Shade R. E., Lee-Kwon W. J., Manning M., Sawyer W. H. The importance of vasopressin in the development and maintenance of DOC-salt hypertension in the rat. Hypertension. 1979 Jan-Feb;1(1):31–38. doi: 10.1161/01.hyp.1.1.31. [DOI] [PubMed] [Google Scholar]
  6. Fujita K., Matsumura Y., Kita S., Hisaki K., Takaoka M., Morimoto S. Phosphoramidon-sensitive conversion of big endothelin-1 and degradation of endothelin-1 in rat kidney. Hypertension. 1994 Aug;24(2):227–233. doi: 10.1161/01.hyp.24.2.227. [DOI] [PubMed] [Google Scholar]
  7. Hexum T. D., Hoeger C., Rivier J. E., Baird A., Brown M. R. Characterization of endothelin secretion by vascular endothelial cells. Biochem Biophys Res Commun. 1990 Feb 28;167(1):294–300. doi: 10.1016/0006-291x(90)91764-j. [DOI] [PubMed] [Google Scholar]
  8. Hughes A. K., Cline R. C., Kohan D. E. Alterations in renal endothelin-1 production in the spontaneously hypertensive rat. Hypertension. 1992 Nov;20(5):666–673. doi: 10.1161/01.hyp.20.5.666. [DOI] [PubMed] [Google Scholar]
  9. Ihara M., Noguchi K., Saeki T., Fukuroda T., Tsuchida S., Kimura S., Fukami T., Ishikawa K., Nishikibe M., Yano M. Biological profiles of highly potent novel endothelin antagonists selective for the ETA receptor. Life Sci. 1992;50(4):247–255. doi: 10.1016/0024-3205(92)90331-i. [DOI] [PubMed] [Google Scholar]
  10. Imai T., Hirata Y., Emori T., Yanagisawa M., Masaki T., Marumo F. Induction of endothelin-1 gene by angiotensin and vasopressin in endothelial cells. Hypertension. 1992 Jun;19(6 Pt 2):753–757. doi: 10.1161/01.hyp.19.6.753. [DOI] [PubMed] [Google Scholar]
  11. Kitamura K., Tanaka T., Kato J., Ogawa T., Eto T., Tanaka K. Immunoreactive endothelin in rat kidney inner medulla: marked decrease in spontaneously hypertensive rats. Biochem Biophys Res Commun. 1989 Jul 14;162(1):38–44. doi: 10.1016/0006-291x(89)91958-x. [DOI] [PubMed] [Google Scholar]
  12. Kohno M., Murakawa K., Horio T., Yokokawa K., Yasunari K., Fukui T., Takeda T. Plasma immunoreactive endothelin-1 in experimental malignant hypertension. Hypertension. 1991 Jul;18(1):93–100. doi: 10.1161/01.hyp.18.1.93. [DOI] [PubMed] [Google Scholar]
  13. Kon V., Badr K. F. Biological actions and pathophysiologic significance of endothelin in the kidney. Kidney Int. 1991 Jul;40(1):1–12. doi: 10.1038/ki.1991.172. [DOI] [PubMed] [Google Scholar]
  14. Kurihara H., Yoshizumi M., Sugiyama T., Takaku F., Yanagisawa M., Masaki T., Hamaoki M., Kato H., Yazaki Y. Transforming growth factor-beta stimulates the expression of endothelin mRNA by vascular endothelial cells. Biochem Biophys Res Commun. 1989 Mar 31;159(3):1435–1440. doi: 10.1016/0006-291x(89)92270-5. [DOI] [PubMed] [Google Scholar]
  15. Larivière R., Thibault G., Schiffrin E. L. Increased endothelin-1 content in blood vessels of deoxycorticosterone acetate-salt hypertensive but not in spontaneously hypertensive rats. Hypertension. 1993 Mar;21(3):294–300. doi: 10.1161/01.hyp.21.3.294. [DOI] [PubMed] [Google Scholar]
  16. Lerman A., Edwards B. S., Hallett J. W., Heublein D. M., Sandberg S. M., Burnett J. C., Jr Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis. N Engl J Med. 1991 Oct 3;325(14):997–1001. doi: 10.1056/NEJM199110033251404. [DOI] [PubMed] [Google Scholar]
  17. Lüscher T. F., Seo B. G., Bühler F. R. Potential role of endothelin in hypertension. Controversy on endothelin in hypertension. Hypertension. 1993 Jun;21(6 Pt 1):752–757. doi: 10.1161/01.hyp.21.6.752. [DOI] [PubMed] [Google Scholar]
  18. Margulies K. B., Hildebrand F. L., Jr, Lerman A., Perrella M. A., Burnett J. C., Jr Increased endothelin in experimental heart failure. Circulation. 1990 Dec;82(6):2226–2230. doi: 10.1161/01.cir.82.6.2226. [DOI] [PubMed] [Google Scholar]
  19. Matsumura Y., Hisaki K., Takaoka M., Morimoto S. Phosphoramidon, a metalloproteinase inhibitor, suppresses the hypertensive effect of big endothelin-1. Eur J Pharmacol. 1990 Aug 21;185(1):103–106. doi: 10.1016/0014-2999(90)90216-s. [DOI] [PubMed] [Google Scholar]
  20. Matsumura Y., Ikegawa R., Suzuki Y., Takaoka M., Uchida T., Kido H., Shinyama H., Hayashi K., Watanabe M., Morimoto S. Phosphoramidon prevents cerebral vasospasm following subarachnoid hemorrhage in dogs: the relationship to endothelin-1 levels in the cerebrospinal fluid. Life Sci. 1991;49(11):841–848. doi: 10.1016/0024-3205(91)90249-b. [DOI] [PubMed] [Google Scholar]
  21. Matsumura Y., Ikegawa R., Takaoka M., Morimoto S. Conversion of porcine big endothelin to endothelin by an extract from the porcine aortic endothelial cells. Biochem Biophys Res Commun. 1990 Feb 28;167(1):203–210. doi: 10.1016/0006-291x(90)91751-d. [DOI] [PubMed] [Google Scholar]
  22. Möhring J., Möhring B., Petri M., Haack D. Vasopressor role of ADH in the pathogenesis of malignant DOC hypertension. Am J Physiol. 1977 Mar;232(3):F260–F269. doi: 10.1152/ajprenal.1977.232.3.F260. [DOI] [PubMed] [Google Scholar]
  23. Nirei H., Hamada K., Shoubo M., Sogabe K., Notsu Y., Ono T. An endothelin ETA receptor antagonist, FR139317, ameliorates cerebral vasospasm in dogs. Life Sci. 1993;52(23):1869–1874. doi: 10.1016/0024-3205(93)90007-p. [DOI] [PubMed] [Google Scholar]
  24. Nishikibe M., Tsuchida S., Okada M., Fukuroda T., Shimamoto K., Yano M., Ishikawa K., Ikemoto F. Antihypertensive effect of a newly synthesized endothelin antagonist, BQ-123, in a genetic hypertensive model. Life Sci. 1993;52(8):717–724. doi: 10.1016/0024-3205(93)90233-s. [DOI] [PubMed] [Google Scholar]
  25. Pollock D. M., Divish B. J., Opgenorth T. J. Stimulation of endogenous endothelin release in the anesthetized rat. J Cardiovasc Pharmacol. 1993;22 (Suppl 8):S295–S298. doi: 10.1097/00005344-199322008-00077. [DOI] [PubMed] [Google Scholar]
  26. Pollock D. M., Opgenorth T. J. Evidence for endothelin-induced renal vasoconstriction independent of ETA receptor activation. Am J Physiol. 1993 Jan;264(1 Pt 2):R222–R226. doi: 10.1152/ajpregu.1993.264.1.R222. [DOI] [PubMed] [Google Scholar]
  27. Rubanyi G. M., Botelho L. H. Endothelins. FASEB J. 1991 Sep;5(12):2713–2720. doi: 10.1096/fasebj.5.12.1916094. [DOI] [PubMed] [Google Scholar]
  28. Sarzani R., Brecher P., Chobanian A. V. Growth factor expression in aorta of normotensive and hypertensive rats. J Clin Invest. 1989 Apr;83(4):1404–1408. doi: 10.1172/JCI114029. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Sogabe K., Nirei H., Shoubo M., Nomoto A., Ao S., Notsu Y., Ono T. Pharmacological profile of FR139317, a novel, potent endothelin ETA receptor antagonist. J Pharmacol Exp Ther. 1993 Mar;264(3):1040–1046. [PubMed] [Google Scholar]
  30. Stein P. D., Hunt J. T., Floyd D. M., Moreland S., Dickinson K. E., Mitchell C., Liu E. C., Webb M. L., Murugesan N., Dickey J. The discovery of sulfonamide endothelin antagonists and the development of the orally active ETA antagonist 5-(dimethylamino)-N-(3,4-dimethyl-5-isoxazolyl)-1-naphthalenesulf onamide. J Med Chem. 1994 Feb 4;37(3):329–331. doi: 10.1021/jm00029a001. [DOI] [PubMed] [Google Scholar]
  31. Suzuki N., Miyauchi T., Tomobe Y., Matsumoto H., Goto K., Masaki T., Fujino M. Plasma concentrations of endothelin-1 in spontaneously hypertensive rats and DOCA-salt hypertensive rats. Biochem Biophys Res Commun. 1990 Mar 30;167(3):941–947. doi: 10.1016/0006-291x(90)90614-s. [DOI] [PubMed] [Google Scholar]
  32. Umekawa T., Matsumura Y., Yoshimura N., Murata S., Takada K., Tsukahara Y., Takaoka M., Morimoto S. Platelets-induced stimulation of endothelin-1 production and inhibition by phosphoramidon. J Pharmacol Exp Ther. 1994 May;269(2):860–866. [PubMed] [Google Scholar]
  33. Vanhoutte P. M. Is endothelin involved in the pathogenesis of hypertension? Hypertension. 1993 Jun;21(6 Pt 1):747–751. doi: 10.1161/01.hyp.21.6.747. [DOI] [PubMed] [Google Scholar]
  34. Vemulapalli S., Watkins R. W., Brown A., Cook J., Bernardino V., Chiu P. J. Disparate effects of phosphoramidon on blood pressure in SHR and DOCA-salt hypertensive rats. Life Sci. 1993;53(10):783–793. doi: 10.1016/0024-3205(93)90500-3. [DOI] [PubMed] [Google Scholar]
  35. Warner T. D., Allcock G. H., Vane J. R. Reversal of established responses to endothelin-1 in vivo and in vitro by the endothelin receptor antagonists, BQ-123 and PD 145065. Br J Pharmacol. 1994 May;112(1):207–213. doi: 10.1111/j.1476-5381.1994.tb13053.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Widimsky J., Jr, Horky K., Dvorakova J. Plasma endothelin-1,2 levels in mild and severe hypertension. J Hypertens Suppl. 1991 Dec;9(6):S194–S195. [PubMed] [Google Scholar]
  37. Yanagisawa M., Kurihara H., Kimura S., Tomobe Y., Kobayashi M., Mitsui Y., Yazaki Y., Goto K., Masaki T. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 1988 Mar 31;332(6163):411–415. doi: 10.1038/332411a0. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES